114 related articles for article (PubMed ID: 8111709)
1. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia.
DeNardo GL; Lewis JP; DeNardo SJ; O'Grady LF
Cancer; 1994 Mar; 73(5):1425-32. PubMed ID: 8111709
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
3. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.
DeNardo GL; DeNardo SJ; Macey DJ; Shen S; Kroger LA
Cancer; 1994 Feb; 73(3 Suppl):1038-48. PubMed ID: 8306246
[TBL] [Abstract][Full Text] [Related]
4. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody.
DeNardo GL; DeNardo SJ; Lamborn KR; Goldstein DS; Levy NB; Lewis JP; O'Grady LF; Raventos A; Kroger LA; Macey DJ; McGahan JP; Mills SL; Shen S
Cancer Biother Radiopharm; 1998 Aug; 13(4):239-54. PubMed ID: 10850360
[TBL] [Abstract][Full Text] [Related]
5. Milestones in the development of Lym-1 therapy.
DeNardo GL; O'Donnell RT; Rose LM; Mirick GR; Kroger LA; DeNardo SJ
Hybridoma; 1999 Feb; 18(1):1-11. PubMed ID: 10211782
[TBL] [Abstract][Full Text] [Related]
6. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy.
Wilder RB; DeNardo GL; Sheri S; Fowler JF; Wessels BW; DeNardo SJ
Eur J Nucl Med; 1996 Aug; 23(8):953-7. PubMed ID: 8753685
[TBL] [Abstract][Full Text] [Related]
7. Analysis of antiglobulin (HAMA) response in a group of patients with B-lymphocytic malignancies treated with 131I-Lym-1.
De Nardo GL; Kroger LA; Mirick GR; Lamborn KR; De Nardo SJ
Int J Biol Markers; 1995; 10(2):67-74. PubMed ID: 7561241
[TBL] [Abstract][Full Text] [Related]
8. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
[TBL] [Abstract][Full Text] [Related]
9. Prolonged survival associated with immune response in a patient treated with Lym-1 mouse monoclonal antibody.
DeNardo SJ; Kroger LA; MacKenzie MR; Mirick GR; Shen S; DeNardo GL
Cancer Biother Radiopharm; 1998 Feb; 13(1):1-12. PubMed ID: 10850337
[TBL] [Abstract][Full Text] [Related]
10. Body and blood clearance and marrow radiation dose of 131I-Lym-1 in patients with B-cell malignancies.
DeNardo GL; Mahe MA; DeNardo SJ; Macey DJ; Mirick GR; Erwin WD; Groch MW
Nucl Med Commun; 1993 Jul; 14(7):587-95. PubMed ID: 8355919
[TBL] [Abstract][Full Text] [Related]
11. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies.
DeNardo SJ; DeNardo GL; O'Grady LF; Hu E; Sytsma VM; Mills SL; Levy NB; Macey DJ; Miller CH; Epstein AL
Int J Cancer Suppl; 1988; 3():96-101. PubMed ID: 3209308
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of lymphoma: a UC Davis experience.
Lewis JP; Denardo GL; Denardo SJ
Hybridoma; 1995 Apr; 14(2):115-20. PubMed ID: 7590765
[TBL] [Abstract][Full Text] [Related]
13. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; Lamborn KR; Levy NB; McGahan JP; Salako Q; Shen S; Lewis JP
J Clin Oncol; 1998 Oct; 16(10):3246-56. PubMed ID: 9779698
[TBL] [Abstract][Full Text] [Related]
14. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
Schillaci O; DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; O'Donnell RT; Lamborn KR
Cancer Biother Radiopharm; 2007 Aug; 22(4):521-30. PubMed ID: 17803447
[TBL] [Abstract][Full Text] [Related]
15. A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.
Kuzel T; Rosen ST; Zimmer AM; Silverstein EA; Spies S; Saletan SL; Norvitch ME; Birkhofer M; Shochat D; LoBuglio AF
Cancer Biother; 1993; 8(1):3-16. PubMed ID: 7812346
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90Y-T101, in patients with CD5-expressing leukemia and lymphoma.
Foss FM; Raubitscheck A; Mulshine JL; Fleisher TA; Reynolds JC; Paik CH; Neumann RD; Boland C; Perentesis P; Brown MR; Frincke JM; Lollo CP; Larson SM; Carrasquillo JA
Clin Cancer Res; 1998 Nov; 4(11):2691-700. PubMed ID: 9829731
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma.
Czuczman MS; Straus DJ; Divgi CR; Graham M; Garin-Chesa P; Finn R; Myers J; Old LJ; Larson SM; Scheinberg DA
J Clin Oncol; 1993 Oct; 11(10):2021-9. PubMed ID: 8410126
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study.
Rosen ST; Zimmer AM; Goldman-Leikin R; Gordon LI; Kazikiewicz JM; Kaplan EH; Variakojis D; Marder RJ; Dykewicz MS; Piergies A
J Clin Oncol; 1987 Apr; 5(4):562-73. PubMed ID: 3549989
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related parameters predicting efficacy of Lym-1 radioimmunotherapy in patients with B-lymphocytic malignancies.
Lamborn KR; DeNardo GL; DeNardo SJ; Goldstein DS; Shen S; Larkin EC; Kroger LA
Clin Cancer Res; 1997 Aug; 3(8):1253-60. PubMed ID: 9815807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
